EMICIZUMAB FOR THE TREATMENT OF INFANTS WITH SEVERE HEMOPHILIA A: INTERIM ANALYSIS OF HAVEN 7

被引：0

作者：

Pipe, Steven ^{[1
]}

Collins, Peter ^{[1
]}

Dhalluin, Christophe ^{[1
]}

Kenet, Gili ^{[1
]}

Schmitt, Christophe ^{[1
]}

Buri, Muriel ^{[1
]}

Jimenez-Yuste, Victor ^{[1
]}

Peyvandi, Flora ^{[1
]}

Young, Guy ^{[1
]}

Oldenburg, Johannes ^{[1
]}

ElisaMancuso, Maria ^{[1
]}

Kiialainen, Anna ^{[1
]}

Chang, Tiffany ^{[1
]}

Lehle, Michaela ^{[1
]}

Fijnvandraat, Karin ^{[1
]}

机构：

[1] Childrens Hosp Los Angeles, Los Angeles, CA USA

来源：

PEDIATRIC BLOOD & CANCER | 2023年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2011

引用

页码：S7 / S7

页数：1

共 50 条

[1] Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study
Pipe, Steven W.
Collins, Peter
Dhalluin, Christophe
Kenet, Gili
Schmitt, Christophe
Buri, Muriel
Jimenez-Yuste, Victor
Peyvandi, Flora
Young, Guy
Oldenburg, Johannes
Mancuso, Maria Elisa
Kiialainen, Anna
Chang, Tiffany
Lehle, Michaela
Fijnvandraat, Karin
BLOOD, 2022, 140
[2] FVIII Exposure Analysis from the HAVEN 7 Study of Emicizumab in Infants with Severe Hemophilia A
Young, Guy
Eakle, Katherine
Lim, Elise
Wang, Michael
BLOOD, 2024, 144 : 2589 - 2590
[3] EMICIZUMAB PROPHYLAXIS FOR THE TREATMENT OF INFANTS WITH SEVERE HEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS: PRIMARY ANALYSIS OF THE HAVEN 7 STUDY
Pipe, Steven W.
Collins, Peter
Dhalluin, Christophe
Kenet, Gili
Schmitt, Christophe
Buri, Muriel
Jimenez-Yuste, Victor
Peyvandi, Flora
Young, Guy
Oldenburg, Johannes
Mancuso, Maria Elisa
Kavakli, Kaan
Kiialainen, Anna
Niggli, Markus
Chang, Tiffany
Lehle, Michaela
Fijnvandraat, Karin
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 100 : 99 - 99
[4] Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7
Kiialainen, Anna
Pipe, Steven
Fijnvandraat, Karin
Kenet, Gili
Schmitt, Christophe
Buri, Muriel
Jimenez-Yuste, Victor
Oldenburg, Johannes
Mancuso, Maria Elisa
Dhalluin, Christophe
Lehle, Michaela
Collins, Peter
BLOOD, 2023, 142
[5] Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study
Pipe, Steven
Collins, Peter
Dhalluin, Christophe
Kenet, Gili
Schmitt, Christophe
Buri, Muriel
Jimenez-Yuste, Victor
Peyvandi, Flora
Young, Guy
Oldenburg, Johannes
Mancuso, Maria Elisa
Kavakli, Kaan
Kiialainen, Anna
Chang, Tiffany
Lehle, Michaela
Niggli, Markus
Fijnvandraat, Karin
BLOOD, 2023, 142
[6] Emicizumab prophylaxis for the treatment of infants with severe haemophilia A without factor VIII inhibitors: primary analysis of the HAVEN 7 study
Pipe, S. W.
Collins, P.
Dhalluin, C.
Kenet, G.
Schmitt, C.
Buri, M.
Jimenez-Yuste, V.
Peyvandi, F.
Young, G.
Oldenburg, J.
Mancuso, M. E.
Kavakli, K.
Kiialainen, A.
Niggli, M.
Chang, T.
Lehle, M.
Fijnvandraat, K.
HAEMOPHILIA, 2024, 30 : 24 - 25
[7] Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial
Pipe, Steven W.
Collins, Peter
Dhalluin, Christophe
Kenet, Gili
Schmitt, Christophe
Buri, Muriel
Jimenez-Yuste, Victor
Peyvandi, Flora
Young, Guy
Oldenburg, Johannes
Mancuso, Maria Elisa
Kavakli, Kaan
Kiialainen, Anna
Deb, Sonia
Niggli, Markus
Chang, Tiffany
Lehle, Michaela
Fijnvandraat, Karin
BLOOD, 2024, 143 (14) : 1355 - 1364
[8] HAVEN 7, Primary Analysis: Infants benefit from early Prophylaxis with Emicizumab
不详
TRANSFUSION MEDICINE AND HEMOTHERAPY, 2024, 51 (03) : 201 - 201
[9] EMICIZUMAB PROPHYLAXIS IN INFANTS WITH SEVERE HEMOPHILIA A: MANAGEMENT OF 6 CASES
Wang, Cassandra
Kizilocak, Hande
Young, Guy
PEDIATRIC BLOOD & CANCER, 2022, 69
[10] Emicizumab in Children with Severe Hemophilia A
Thota, Usha Rani
Martha, Sreelatha
Ravula, Chaitanya Jyothi
Cherukuri, Nirmala
INDIAN JOURNAL OF PEDIATRICS, 2024,

← 1 2 3 4 5 →